Ovarian-Sparing Surgery for Early Stage Adult Granulosa Cell Tumors Survival Benefits and Risks
A diagnosis of an adult granulosa cell tumour can feel confusing because it is rare, slow-growing, and very different from the ovarian cancers most people have heard about. For someone with an early-stage tumour, one of the most sensitive treatment questions is this: can surgery remove the cancer while preserving fertility and hormonal function?
For selected patients, the answer may be yes. OVARIAN-SPARING SURGERY can be a reasonable option in early-stage adult granulosa cell tumours, especially when the disease appears limited to one ovary. But the decision is never simple. Survival is only one part of the discussion. Doctors also weigh the risk of recurrence, the patient’s age, fertility goals, tumour features, surgical findings, and the need for long-term follow-up.
This article explains what current research suggests, where uncertainty remains, and why treatment should be tailored rather than automatic.
This content is for general information only and cannot replace medical advice from a qualified gynaecologic oncologist.
What adult granulosa cell tumours are
Adult granulosa cell tumours, often shortened to AGCTs, are rare ovarian tumours that arise from sex cord-stromal cells. These cells normally help support egg development and hormone production in the ovary.
Unlike high-grade epithelial ovarian cancers, AGCTs usually grow more slowly. Many are diagnosed at an early stage, often stage I, meaning the tumour is confined to the ovary or ovaries. Some produce oestrogen, which can cause symptoms such as:
Irregular or heavy menstrual bleeding
Bleeding after menopause
Pelvic pain or pressure
Abdominal bloating
An ovarian mass found during imaging
Because these tumours can make oestrogen, doctors may also assess the lining of the uterus, called the endometrium. In some patients, prolonged oestrogen exposure can lead to endometrial hyperplasia, which means thickening of the uterine lining, or rarely endometrial cancer.
A key feature of AGCTs is their long natural history. Even after successful treatment, recurrence can occur many years later. This is why follow-up often continues for decades, not just for five years.
What ovarian-sparing surgery means in this setting
The term can be used in different ways, so clarity matters.
In early-stage adult granulosa cell tumours, ovarian-sparing or fertility-sparing surgery usually means removing the ovary and fallopian tube affected by the tumour while preserving the uterus and the other ovary. The medical term is unilateral salpingo-oophorectomy.
In carefully selected situations, surgeons may consider removing only the tumour from the ovary, called cystectomy. This is less common for AGCTs because it may leave behind microscopic disease or increase the risk of tumour rupture. Many specialists prefer removing the affected ovary when cancer is confirmed or strongly suspected.
The more extensive option is radical surgery, which may include removal of both ovaries, both fallopian tubes, and the uterus. This approach removes future fertility and causes surgical menopause if the patient has not already reached menopause.
The surgical plan may also include staging procedures. These help confirm how far the tumour has spread and can include:
Careful inspection of the abdomen and pelvis
Peritoneal washings, where fluid is tested for cancer cells
Biopsy of suspicious areas
Removal of the omentum in selected cases
Endometrial sampling when clinically appropriate
Routine lymph node removal is not always needed because lymph node spread is uncommon in early AGCTs. Many experts now favour targeted assessment rather than extensive lymph node surgery when nodes look normal.
What survival research suggests so far
Research on AGCTs is challenging because the condition is rare. Most evidence comes from retrospective studies, cancer registry analyses, and systematic reviews rather than large randomised trials. That means the findings are useful, but they must be read with caution.
Across recent studies, one pattern appears consistent: for carefully selected patients with stage I disease, fertility-sparing surgery does not seem to reduce overall survival compared with more radical surgery.
This is especially relevant for stage IA disease, where the tumour is limited to one ovary, the capsule is intact, and there is no tumour found on the surface of the ovary or in abdominal fluid. In this group, survival outcomes are generally favourable after complete surgical removal.
Research also suggests that recurrence risk depends on more than the choice to preserve the uterus or opposite ovary. Factors that may influence recurrence include:
Stage at diagnosis
Tumour rupture before or during surgery
Tumour size
Residual disease after surgery
Certain microscopic features seen by the pathologist
Whether staging was complete
Length and quality of follow-up
Survival and recurrence are not the same. A patient may have a recurrence years later and still receive successful treatment. Because AGCTs often grow slowly, long-term survival can remain good even when recurrence occurs. Still, recurrence can require further surgery, hormonal treatment, chemotherapy in selected cases, or other therapies.
The central message from current evidence is cautious support, not blanket approval. Fertility-sparing surgery appears safe for many early-stage patients, but only after careful staging, expert review, and long-term monitoring.
Why the approach can matter so much
For younger patients or those who have not completed their families, preserving the uterus and one ovary can be life-changing. It may allow future pregnancy and avoid immediate menopause.
Potential benefits include:
Preservation of fertility
Keeping the uterus and one ovary may allow natural conception or assisted reproduction, depending on age and ovarian function.
Avoidance of early menopause
Preserving one functioning ovary can help maintain natural hormone production. This may protect bone health, sexual health, cardiovascular health, mood, and quality of life.
Less extensive surgery
A more limited operation may reduce surgical impact in selected patients, though cancer safety remains the priority.
Psychological benefit
For some patients, keeping fertility options open helps reduce distress after diagnosis.
These benefits are meaningful, but they cannot override oncological safety. The tumour must be removed completely, and the surgical team must be confident that disease has not spread.
The risks that need careful discussion
The main concern with ovarian-sparing surgery is recurrence. If the remaining ovary is preserved, there is a possibility that disease may later appear in that ovary or elsewhere in the abdomen or pelvis. This risk may be low in well-selected stage IA patients, but it is not zero.
Some risks relate to the tumour itself, while others relate to surgery.
Tumour rupture
If the tumour capsule breaks, cancer cells may spill into the pelvis. Rupture can happen before surgery or during the operation. This may change the stage and can affect recurrence risk.
Incomplete staging
If the first surgery removes the mass but does not include proper staging, doctors may not know the true extent of disease. Some patients may need a second operation for staging, especially if the initial surgery was done before cancer was suspected.
Hidden uterine changes
Because some AGCTs produce oestrogen, the uterine lining may need assessment. Preserving the uterus without checking symptoms such as abnormal bleeding may miss another condition.
Long-term recurrence
AGCTs are known for late recurrence. A clear scan and normal examination in the first few years do not remove the need for follow-up.
Emotional burden
Monitoring for recurrence can be stressful. Some patients prefer more extensive surgery for peace of mind, especially after completing their families.
The best choice balances cancer control with personal goals. A technically possible fertility-sparing operation is not always the right operation.
Patient case studies that show how decisions vary
The following anonymised scenarios are illustrative. They reflect common clinical patterns but are not substitutes for personal medical advice.
Case study one shows a favourable setting for fertility preservation
A 29-year-old woman had an ovarian mass found after months of irregular bleeding and pelvic discomfort. Imaging showed a mass limited to the left ovary. Blood tests and scans did not suggest spread. She wanted future pregnancy.
During surgery, the team removed the left ovary and fallopian tube, preserved the uterus and right ovary, and performed staging steps. The capsule was intact. Final pathology confirmed stage IA adult granulosa cell tumour. Endometrial sampling showed no cancer.
After counselling, she chose surveillance rather than further surgery. Follow-up included pelvic examination, imaging when needed, and tumour markers such as inhibin B or anti-Müllerian hormone where available. Several years later, she remained disease-free and retained menstrual function.
This type of case is where fertility-sparing surgery is most often considered appropriate.
Case study two shows why caution is needed
A 38-year-old woman underwent emergency surgery for a large ovarian mass that had twisted and caused severe pain. The mass ruptured during removal. Pathology later showed adult granulosa cell tumour. Initial staging had not been completed because cancer was not suspected at the time.
Her care team reviewed the case in a tumour board setting. They discussed repeat staging surgery, the risk linked with rupture, her fertility wishes, and the option of completing surgery after childbearing. She chose further staging and close surveillance while preserving the uterus and other ovary.
This case shows why the first operation matters. When AGCT is diagnosed after surgery, further decisions may be more complex.
Case study three shows a different priority after menopause
A 56-year-old postmenopausal woman had bleeding and was found to have an ovarian mass. Because she had completed childbearing and had symptoms suggesting oestrogen effect on the uterus, her team recommended removal of the uterus, both ovaries, and both fallopian tubes, along with staging.
Her final tumour was early stage. She avoided the need to monitor a remaining ovary, and the uterine lining was assessed fully. For her, fertility preservation had no benefit, so a more complete surgery made sense.
The lesson is simple: early-stage disease does not mean one operation fits everyone.
How experts usually frame the decision
Gynaecologic oncologists tend to look at ovarian-sparing surgery through two lenses: oncological safety and the patient’s life goals.
Their advice often includes these points:
Fertility-sparing surgery is most suitable for young patients with apparent stage IA disease.
The affected ovary is usually removed rather than peeled out, because cystectomy may carry more risk.
Proper staging is important, even when scans look reassuring.
The uterus can often be preserved when fertility is desired, but abnormal bleeding should be investigated.
Patients need long-term follow-up because late recurrence is a known feature of AGCT.
Completion surgery may be discussed after childbearing, though the timing varies by patient and risk profile.
Many specialists also stress shared decision-making. This means the doctor explains survival data, recurrence risk, uncertainty, and alternatives in plain language, while the patient’s values are included in the final plan.
A useful expert way to describe the choice is this: the goal is not the smallest surgery. The goal is the safest surgery that preserves what can reasonably be preserved.
What follow-up usually involves
Surveillance after treatment is not a minor detail. It is part of the treatment plan.
Follow-up may include:
Regular clinical review and pelvic examination
Ultrasound, CT, or MRI when symptoms or findings suggest concern
Blood markers such as inhibin A, inhibin B, or anti-Müllerian hormone if they were raised at diagnosis
Review of menstrual changes or abnormal bleeding
Long-term monitoring beyond the usual five-year cancer window
The exact schedule varies. Some patients need closer follow-up in the first few years, then less frequent visits later. Because AGCTs can recur late, stopping follow-up too early may miss treatable recurrence.
Patients should report new pelvic pain, bloating, abnormal bleeding, unexplained weight changes, or changes in menstrual pattern. These symptoms do not always mean recurrence, but they should be checked.
The role of ongoing research
The evidence base is growing, but key questions remain unanswered.
Researchers are studying better ways to predict recurrence, including molecular markers such as the FOXL2 mutation, which is commonly associated with adult granulosa cell tumours. This mutation helps support diagnosis, but doctors still need stronger tools to predict which early-stage tumours are more likely to return.
Other research areas include:
The safest extent of fertility-sparing surgery
Which patients need completion surgery later
The best surveillance schedule and blood markers
The role of hormonal therapy in recurrent disease
Quality-of-life outcomes after different surgical choices
Fertility and pregnancy outcomes after treatment
Because AGCTs are rare, progress depends on multi-centre research, cancer registries, and long follow-up. Short studies may miss late recurrences, so future evidence needs time as much as patient numbers.
A balanced takeaway for early-stage AGCT care
Ovarian-sparing surgery offers a valuable path for selected patients with early-stage adult granulosa cell tumours. Current research suggests that, especially in stage IA disease, preserving the uterus and one ovary can provide good survival outcomes while maintaining fertility potential and hormonal function.
The benefits are real, but so are the risks. Recurrence can occur years later. Tumour rupture, incomplete staging, higher-risk pathology, or uncertainty about spread can change the balance. That is why decisions should be made with a gynaecologic oncologist, supported by pathology review, appropriate staging, and honest discussion of personal goals.
The strongest plan is an individualised one: remove the tumour safely, preserve fertility when it is reasonable, investigate hormone-related uterine changes, and commit to long-term follow-up. As research improves, patients and clinicians should gain better tools to identify who can safely benefit from ovarian preservation and who needs a more extensive approach from the start.
Comments